Who will buy Qiagen?
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
Storm-tossed Qiagen plots a course to higher growth
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Esmo 2019 – Foundation eyes liquid biopsy rule change
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
World Lung 2019 – Oncimmune’s liquid biopsy hits in large trial
The data are positive, but might not do much for the company’s sales.
Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Thrive emerges with cash, a cancer blood test, and a plan
A new player has entered the liquid biopsy game.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Asco 2019 – Guardant and Grail square up
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.